Yuyu Pharma’s CEO, Robert Yu, attended two major biopharmaceutical conferences in Germany—BIO-Europe in Leipzig and CPHI in Frankfurt—aiming to expand the company’s presence in international markets, including Europe. During these conferences, Robert Yu engaged with contract research organizations, Key Opinion Leaders, and potential clinical sites to prepare for clinical trials in the U.S. and Europe for Yuyu’s promising drugs, YP-P10 for dry eye and DUT for androgenetic alopecia.

Currently, Yuyu Pharma is conducting Phase 2 clinical trials for YP-P10 in the U.S., with 240 patients across seven clinical sites. Yu also used the conferences to explore collaboration opportunities with global pharmaceutical companies and meet with European officials to discuss regulatory matters and drug registration processes.

Robert Yu expressed optimism about the feedback Yuyu Pharma received on its new drug pipeline, stating that the conferences provided a valuable platform to introduce the company and its development programs. Yuyu Pharma, a Korean company founded in 1941, focuses on improving quality of life through innovative therapeutics in neurology, urology, and ophthalmology. The company continues to seek growth opportunities worldwide, expanding its reach and portfolio.